Epcoritamab SC + GemOx Leads to High Complete Metabolic Response Rates in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Ineligible for Autologous Stem Cell Transp... von Brody, Joshua, Joergensen, Judit Mészáros, Belada, David, Costello, Regis T., Trněný, Marek, Vitolo, Umberto, Lewis, David, Karimi, Yasmin H., Sureda Balari, Anna Maria, André, Marc, Wahlin, Björn E., Lugtenburg, Pieternella, Galderisi, Faith, Abbas, Aqeel, Song, Yaou, Risum, Malene, Cordoba, Raul

Volltext

Efficacy and Safety of Golcadomide, a Novel Cereblon E3 Ligase Modulator (CELMoD) Agent, Combined with Rituximab in a Phase 1/2 Open-Label Study of Patients with Relapsed/Refractor... von Chavez, Julio C., Nastoupil, Loretta J., Morschhauser, Franck, Cartron, Guillaume, Joergensen, Judit Mészáros, Bachy, Emmanuel, Bories, Pierre, Campbell, Victoria, Fontanet, Bijou, Patah, Poliana P., de Moucheron, Bérengère, Carrancio, Soraya, Zheng, Xirong, Mei, Chaoqun, Pourdehnad, Michael, Michot, Jean-Marie

Volltext

Differences in Overall Survival for Non-Western Immigrant Patients Compared to Danish-Born Patients with Diffuse Large B-Cell Lymphoma von Simonsen, Mikkel Runason, Jakobsen, Lasse Hjort, Severinsen, Marianne Tang, Frederiksen, Henrik, Niemann, Carsten Utoft, Joergensen, Judit Mészáros, Clausen, Michael Roost, Starklint, Jørn, Johnsen, Søren Paaske, El-galaly, Tarec Christoffer, Baech, Joachim

Volltext

Glofitamab (Glofit) Plus R-CHOP Has a Favorable Safety Profile and Induces High Response Rates in Patients with Previously Untreated (1L) Large B-Cell Lymphoma (LBCL) Defined As Hi... von Falchi, Lorenzo, Jardin, Fabrice, Haioun, Corinne, Wrobel, Tomasz, Joergensen, Judit Mészáros, Bastos-Oreiro, Mariana, Mou, Eric, Martinez-Lopez, Joaquin, Budde, L. Elizabeth, Bartlett, Nancy L., Zaucha, Jan M., Martin Garcia-Sancho, Alejandro, Shah, Rutanshu, Rees, Nathan, McCord, Ron, Bazeos, Alexandra, Tandon, Maneesh, Doral, Michelle, Troy-Barnes, Ethan, Nijland, Marcel

Volltext

Glofitamab Plus Polatuzumab Vedotin Continues to Demonstrate Frequent and Durable Responses and Has a Manageable Safety Profile in Patients with ≥2L Relapsed/Refractory DLBCL, Incl... von Hutchings, Martin, Avigdor, Abraham, Sureda Balari, Anna Maria, Terol, Maria José, Bosch, Francesc, Corradini, Paolo, Larsen, Thomas S., Rueda Dominguez, Antonio, Skarbnik, Alan, Joergensen, Judit Mészáros, Lavie, David, Gurion, Ronit, Zinzani, Pier Luigi, Pinto, Antonio, Cordoba, Raul, Bottos, Alessia, Li, Donghang, Relf, James, Filézac De L'Étang, Audrey, Sellam, Gila, Gritti, Giuseppe

Volltext

Safety and efficacy of PD-L1 inhibitor durvalumab with R-CHOP or R 2 -CHOP in subjects with previously untreated, high-risk DLBCL von Nowakowski, Grzegorz S., Willenbacher, Wolfgang, Greil, Richard, Larsen, Thomas Stauffer, Patel, Krish, Jäger, Ulrich, Manges, Robert F., Trumper, Lorenz H., Haioun, Corinne, Everaus, Hele, Kalakonda, Nagesh, Knoble, Jeanna, Brown, Peter, Joergensen, Judit Meszaros, Cunningham, David, Domper, Neus, Casadebaig, Marie-Laure, Manzke, Oliver, Munoz, Javier

Volltext